Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.40 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.40 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.40 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4773225 | 0.85 | MEN1 (0.43) | CYP2A6EGLN2ABCC9ABCC8KCNJ11 | |
| SCHEMBL8874836 | 0.84 | CYP2A6 (0.47) | CYP2A6EGLN2ABCC9ABCC8KCNJ11 | |
| SCHEMBL534995 | 0.82 | ALDH1A1 (0.41) | CYP2A6EGLN2TRPV4MEN1TTR | |
| SCHEMBL4767252 | 0.82 | TSHR (0.42) | CYP2A6MEN1TTRALBKMT2A | |
| SCHEMBL1232330 | 0.82 | MEN1 (0.39) | CYP2A6MEN1TTRALBKMT2A | |
| SCHEMBL13824727 | 0.81 | CYP2A6 (0.52) | CYP2A6EGLN2ABCC9ABCC8KCNJ11 | |
| SCHEMBL19410044 | 0.80 | LOXL2 (0.38) | CYP2A6ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL15721486 | 0.80 | TSHR (0.49) | CYP2A6MEN1KMT2AALDH1A1 | |
| SCHEMBL16960983 | 0.80 | GABRA1 (0.35) | GABRA1GABRB2 | |
| SCHEMBL500133 | 0.80 | MEN1 (0.42) | MEN1TTRALBKMT2AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3708163-A1 | USE OF SPARSENTAN FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | Ligand Pharmaceuticals, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10287286-B2 | Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-14 | — | — | US | disclosed |
| US-9993461-B2 | Method for treating disorders associated with glomerular function | LIGAND PHARMACEUTICALS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20180072714-A1 | Novel Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20170354646-A1 | METHOD FOR TREATING DISORDERS ASSOCIATED WITH GLOMERULAR FUNCTION | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-12-14 | — | — | US | disclosed |
| EP-3222277-A1 | A DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR ANTAGONISTS TO TREATGLOMERULOSCLEROSIS | Ligand Pharmaceuticals Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9662312-B2 | Method for treating glomerulosclerosis | LIGAND PHARMACEUTICALS INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150164865-A1 | ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-06-18 | — | — | US | disclosed |
| US-20140142149-A1 | ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY | LIGAND PHARMACEUTICALS INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-1638551-B1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2011-12-21 | — | — | EP | disclosed |
| WO-2008074820-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074820-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| CN-1787817-A | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2006-06-14 | — | — | CN | disclosed |
| US-7060697-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2006-06-13 | — | — | US | disclosed |
| EP-1638551-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-03-29 | — | — | EP | disclosed |
| US-20050014724-A1 | Immunosuppressant compounds and compositions | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2005-01-20 | — | — | US | disclosed |
| WO-2004103309-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2004-12-02 | — | — | WO | disclosed |
| US-5801170-A | Heterocyclic biphenylylamides useful as 5HT1D antagonists | SMITHKLINE BEECHAM PLC (GB) | 1998-09-01 | — | — | US | disclosed |
| EP-0733048-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015954-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072714-A1 | Novel Compounds | F12, HAX1, C1S | CYP2A6 125/4885EGLN2 1153/4885ABCC9 740/4885 |
| US-20140142149-A1 | ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY | AGTR2, EDNRB, EDNRA | CYP2A6 731/4885EGLN2 97/4885ABCC9 532/4885 |
| US-10287286-B2 | Compounds | F12, C1S, F3 | CYP2A6 69/4885EGLN2 1321/4885ABCC9 332/4885 |
| US-20170354646-A1 | METHOD FOR TREATING DISORDERS ASSOCIATED WITH GLOMERULAR FUNCTION | REN, AGTR2, AGTR1 | CYP2A6 453/4885EGLN2 279/4885ABCC9 1075/4885 |
| US-20150164865-A1 | ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY | AGTR2, EDNRB, EDNRA | CYP2A6 731/4885EGLN2 97/4885ABCC9 532/4885 |
| US-20050014724-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | CYP2A6 1031/4885EGLN2 2775/4885ABCC9 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.